Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date: June 12, 2025
Event: Regulation FD Disclosure regarding an analyst and investor event held in New York City. The report details updates on the U.S. launch of Motiva implants and future product timelines.
Key Financial Metrics
The filing does not provide audited financial statements, historical revenue, profit, cash flow, margins, debt, or liquidity figures. It contains only preliminary forward-looking sales estimates for a specific product line.
- Q2 Fiscal 2025 Motiva Sales (U.S.): Expected to be between $9.5 million and $10 million.
- Surgeon Adoption: Over 1,000 surgeons now offer Motiva implants in the United States.
Material Changes and Operational Updates
While no comparative financial data is provided, the filing highlights significant operational milestones:
- Motiva Launch: Significant expansion in the U.S. market with over 1,000 participating surgeons.
- Regulatory Filings: The Company expects to file for U.S. FDA approval of Motiva Implants for reconstruction use in the fourth quarter of 2025.
- Product Pipeline: The launch of Preservé in the United States is expected in the first half of 2026.
Guidance, Outlook, and Risks
Outlook: Management provided specific sales guidance for Motiva in Q2 Fiscal 2025 ($9.5M–$10M) and regulatory timelines for reconstruction approval and new product launches.
Risks and Disclaimers:
- Forward-Looking Statements: The report contains estimates that are not a substitute for full interim or annual financial statements prepared under U.S. GAAP.
- Unaudited Data: The preliminary financial data has not been audited, reviewed, or compiled by CBIZ CPAs P.C., the Company's independent registered public accounting firm. No assurance is expressed regarding this data.
- Liability: The information is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the actual Q2 Fiscal 2025 revenue figures in the upcoming interim financial statements to confirm the $9.5M–$10M Motiva sales estimate.
- Monitor the fourth quarter of 2025 for the official FDA submission regarding Motiva reconstruction approval.
- Review the full presentation materials (Exhibit 99.1) for additional context on the surgeon adoption rate and market strategy.
- Confirm the timeline for the Preservé U.S. launch in the first half of 2026 through future regulatory or corporate announcements.